PL2611439T3 - Podanie pozajelitowe oleju rybnego/DHA +EPA przed lub wraz z rozpoczęciem chemioterapii - Google Patents

Podanie pozajelitowe oleju rybnego/DHA +EPA przed lub wraz z rozpoczęciem chemioterapii

Info

Publication number
PL2611439T3
PL2611439T3 PL11746585T PL11746585T PL2611439T3 PL 2611439 T3 PL2611439 T3 PL 2611439T3 PL 11746585 T PL11746585 T PL 11746585T PL 11746585 T PL11746585 T PL 11746585T PL 2611439 T3 PL2611439 T3 PL 2611439T3
Authority
PL
Poland
Prior art keywords
dha
commencement
epa
chemotherapy
composition
Prior art date
Application number
PL11746585T
Other languages
English (en)
Inventor
Ewald Schlotzer
Barbara Krampitz
Ulrich Suchner
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43244801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2611439(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of PL2611439T3 publication Critical patent/PL2611439T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11746585T 2010-09-03 2011-08-26 Podanie pozajelitowe oleju rybnego/DHA +EPA przed lub wraz z rozpoczęciem chemioterapii PL2611439T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37977510P 2010-09-03 2010-09-03
EP10175293A EP2425833A1 (de) 2010-09-03 2010-09-03 Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
PCT/EP2011/064693 WO2012028543A1 (de) 2010-09-03 2011-08-26 Zusammensetzung umfassend eine kombination von dha und epa zur gabe vor beginn der chemotherapie
EP11746585.6A EP2611439B1 (de) 2010-09-03 2011-08-26 Die parenterale applikation von fischöl/dha +epa vor bzw. mit beginn der chemotherapie

Publications (1)

Publication Number Publication Date
PL2611439T3 true PL2611439T3 (pl) 2018-09-28

Family

ID=43244801

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11746585T PL2611439T3 (pl) 2010-09-03 2011-08-26 Podanie pozajelitowe oleju rybnego/DHA +EPA przed lub wraz z rozpoczęciem chemioterapii

Country Status (12)

Country Link
US (2) US20130197087A1 (pl)
EP (2) EP2425833A1 (pl)
CN (1) CN103200939A (pl)
DK (1) DK2611439T3 (pl)
ES (1) ES2664568T3 (pl)
HR (1) HRP20180787T1 (pl)
LT (1) LT2611439T (pl)
NO (1) NO2611439T3 (pl)
PL (1) PL2611439T3 (pl)
PT (1) PT2611439T (pl)
TR (1) TR201807070T4 (pl)
WO (1) WO2012028543A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540292A1 (en) * 2011-06-28 2013-01-02 Nestec S.A. DHA and EPA in the reduction of oxidative stress
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
CN106390122A (zh) * 2015-07-31 2017-02-15 舟山三合生物科技有限公司 化疗类抗癌药口服制剂组合物
EP3525781B2 (en) 2016-10-11 2024-04-24 Fresenius Kabi Deutschland GmbH Composition comprising epa and dha for an enhanced efficacy of anticancer agents
CN106995448B (zh) * 2017-04-17 2019-04-30 西安医学院 一种dha-丝裂霉素c衍生物及其制备方法和应用
CA3062798A1 (en) 2017-05-09 2018-11-15 Baxter Healthcare Sa Parenteral nutrition diagnostic system, apparatus, and method
IL304863B2 (en) 2017-09-11 2025-08-01 Atossa Therapeutics Inc Methods for making and using endoxifen
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
CN111714616A (zh) * 2019-07-17 2020-09-29 江苏西宏生物医药有限公司 一种用于抗肿瘤的组合物
CN115845056A (zh) * 2022-07-22 2023-03-28 山东大学齐鲁医院 DHA通过抑制心肌细胞中p38/ET-1通路在防治放射性心肌纤维化中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
US6949064B2 (en) * 2000-10-20 2005-09-27 Bard Brachytherapy, Inc. Brachytherapy seed deployment system
US20030068385A1 (en) * 2001-03-23 2003-04-10 Moyer Mary Pat Accelerated action fatty acid (AAFA) promotes health of normal tissues and minimizes the toxic side effects of chemotherapy
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
DE10224171A1 (de) 2002-05-31 2003-12-18 Fresenius Kabi Austria Gmbh Gr Pharmazeutische Zusammensetzung, die Arsentrioxid und mindestens eine langkettige, mehrfach ungesättigte Fettsäure umfaßt
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US9034389B2 (en) * 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
PT3278665T (pt) * 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas

Also Published As

Publication number Publication date
CN103200939A (zh) 2013-07-10
HRP20180787T1 (hr) 2018-06-29
LT2611439T (lt) 2018-06-25
PT2611439T (pt) 2018-04-17
ES2664568T3 (es) 2018-04-20
US9675574B2 (en) 2017-06-13
EP2611439A1 (de) 2013-07-10
EP2611439B1 (de) 2018-02-21
EP2425833A1 (de) 2012-03-07
US20150297549A1 (en) 2015-10-22
TR201807070T4 (tr) 2018-06-21
WO2012028543A1 (de) 2012-03-08
DK2611439T3 (en) 2018-06-06
US20130197087A1 (en) 2013-08-01
NO2611439T3 (pl) 2018-07-21

Similar Documents

Publication Publication Date Title
PL2611439T3 (pl) Podanie pozajelitowe oleju rybnego/DHA +EPA przed lub wraz z rozpoczęciem chemioterapii
GB2494787B (en) Neuro-protective effects of adelostemma gracillimum and its isolated compounds
TWI563841B (en) Synchronization of multimedia streams
PH12013500780A1 (en) Alkoxylated fatty esters and derivatives from natural oil metathesis
EP2560484A4 (en) PHARMACEUTICAL COMPOSITION FROM NANOPARTICLES
ZA201402479B (en) Bag and its use to provide admixture for a hydraulic composition
PT2797601T (pt) Composições farmacêuticas para reduzir complicações de esteroide ocular
GB2482900B (en) Delivery of compositions to arthropods
IL250751A0 (en) Vitamin d3 and its analogues for the relief of chemotherapy-related side effects
PL2704589T3 (pl) Kompozycje zawierające antymetabolity glukozy i selen
PL2798450T3 (pl) Sposób wyświetlania elementów
IL217988A0 (en) Pharmaceutical composition including a dha ester to be parenterally administered
ZA201207948B (en) Pharmaceutical composition of ibuprofen for injection
GB201204849D0 (en) Synchronising the transient state of content in a counterpart application
GB201015360D0 (en) Improvements in relation to table
ZA201305342B (en) Improvements in and relating to compositions
IL228519A (en) Preparation of 5,3-dioxohexanoate ester in two stages
HK1186971A (en) Composition comprising a combination of dha and epa for administration prior to commencement of chemotherapy
TWM433066U (en) Connector capable of crossing chair foot to be component stand
ZA201300098B (en) Pharmaceutical composition with enhanced solubility characteristics
SG10201605371SA (en) Alkoxylated fatty esters and derivatives from natural oil metathesis
GB201009294D0 (en) The collapsible cupola and pipe to eliminate the effects of oil spill
IL212611A0 (en) Adding content of third party objects to visual presentations
GB201102387D0 (en) Dietary supplement composition
GB201101738D0 (en) Improvements in and relating to compositions